Cannabidiolic acid (CBDA) has attracted growing interest as a raw, unheated precursor to CBD, yet its side-effect profile in humans remains remarkably poorly defined. The handful of clinical observations available suggest that gastrointestinal discomfort is the most commonly reported complaint with oral hemp-derived products, and lab studies raise legitimate concerns about drug interactions. But the honest picture is that controlled human trials of CBDA specifically are almost nonexistent, so much of what we know is stitched together from animal pharmacology, CBD research, and post-marketing reports from products that contain CBDA alongside other cannabinoids.
Why the Evidence Is So Thin
CBDA is chemically unstable. It is the acidic form of CBD, present in raw cannabis and hemp, and it converts to CBD when exposed to heat, light, or even prolonged storage at room temperature. That instability makes it difficult to manufacture into a reliable drug product and even harder to study in the kind of large, long-running clinical trials that would reveal side effects clearly. A 2025 review of acidic cannabinoids put it plainly: chemical instability, low bioavailability, and a lack of controlled human trials are the main obstacles holding back clinical translation of CBDA despite its therapeutic promise.1PubMed Central. Therapeutic potential of acidic cannabinoids: an update
This means that when you see claims about CBDA side effects online, they are usually extrapolated from CBD data, inferred from CBDA’s known pharmacology, or based on post-marketing surveillance of products that contain a mixture of cannabinoids. That is not the same as a placebo-controlled trial where one group takes pure CBDA and another takes a sugar pill. Keep that gap in mind for everything that follows.
Gastrointestinal Discomfort
The most frequently reported side effect of oral hemp-derived products is gastrointestinal trouble. A two-year post-marketing safety review of a full-spectrum hemp extract found that abdominal discomfort was the most common complaint among people who took the product by mouth.2PubMed. Post Marketing Safety of Plus CBDâ„¢ Products, a Full Spectrum Hemp Extract: A 2-Year Experience Full-spectrum products contain CBDA along with CBD, trace amounts of THC, terpenes, and other plant compounds, so isolating which ingredient caused the stomach upset is not straightforward. Still, GI complaints are consistently the top category across oral cannabinoid products, and there is no reason to expect CBDA-rich formulations to be an exception.
There is an irony here. CBDA is one of the most potent anti-nausea compounds identified in the cannabis plant. In animal studies, CBDA suppressed nausea-related behavior at doses thousands of times lower than those needed for CBD, working through serotonin 5-HT1A receptors in the brain.3PubMed Central. Cannabidiolic acid prevents vomiting in Suncus murinus and nausea-induced behaviour in rats by enhancing 5-HT1A receptor activation Repeated dosing over seven days produced the same anti-nausea effect without apparent tolerance building up.4PubMed. Evaluation of repeated or acute treatment with cannabidiol (CBD), cannabidiolic acid (CBDA) or CBDA methyl ester (HU-580) on nausea and/or vomiting in rats and shrews So at small doses, CBDA may actually relieve nausea rather than cause it. But at higher oral doses, the carrier oils, other plant compounds, or sheer concentration of cannabinoid hitting the gut lining may provoke the very symptoms CBDA is being studied to prevent. Until dose-finding studies in humans clarify the sweet spot, mild stomach discomfort remains the side effect you are most likely to experience.
CBDA Gets Into Your Blood More Easily Than CBD
One of the most practically important things about CBDA is how much more of it reaches the bloodstream compared to CBD when you take the same dose by mouth. In a study of horses given equal oral doses, CBDA reached peak blood levels up to 67 times higher than CBD, and the total drug exposure over time was up to 36 times greater.5PubMed Central. Differences in Plasma Exposure of Cannabidiol and Cannabidiolic Acid Following Oral Administration to Horses A separate study in dogs found a similar pattern: CBDA isolate reached peak concentrations roughly three times higher than CBD isolate, with about three times the overall exposure.6PubMed Central. Limited 12-hour pharmacokinetic assessment of CBD and CBDA isolates compared to their full-spectrum extracts in healthy adult beagles
These are animal studies, and the exact ratios in humans may differ. But the direction of the finding is consistent enough to matter. If CBDA is absorbed dramatically better than CBD, then a dose that seems modest on the label could deliver far more active compound into your system than you would expect based on CBD experience. That higher internal exposure could amplify whatever side effects CBDA shares with CBD, including drowsiness, GI complaints, and drug interactions. It also means you probably need a lower milligram dose of CBDA to get a given effect, which is good news for efficacy but a caution for people who dose CBDA the way they dose CBD.
Drug Interactions Through Liver Enzymes
This is where the side-effect picture gets most concerning, especially for people taking prescription medications. Like CBD and most other cannabinoids, CBDA inhibits certain liver enzymes that your body uses to break down drugs. The enzyme family that matters most here is CYP2C9. A lab study looking at a wide range of cannabinoids found that nearly all of them inhibited CYP2C9 at concentrations relevant to real-world dosing, and concluded that drug interaction studies may be warranted for anyone taking CYP2C9 substrates with a narrow safety margin.7PubMed. Cannabinoid Interactions with Cytochrome P450 Drug Metabolism: a Full-Spectrum Characterization
What is a CYP2C9 substrate with a narrow safety margin? The most clinically important one is warfarin, a blood thinner used by millions of people. When cannabinoids block the enzyme that metabolizes warfarin, the drug sticks around longer and at higher levels, increasing the risk of bleeding. A study directly testing cannabis extracts against warfarin metabolism confirmed that both pure cannabinoids and whole-plant extracts inhibited the main pathway warfarin uses to get cleared from the body. The extracts were actually more potent inhibitors than would have been predicted from the individual cannabinoid concentrations alone, suggesting that the combined effect of multiple cannabinoids is greater than the sum of its parts.8Medical Cannabis and Cannabinoids. Phytochemical Comparison of Medicinal Cannabis Extracts and Study of Their CYP-Mediated Interactions with Coumarinic Oral Anticoagulants
CBDA specifically has also been studied for enzyme inhibition in veterinary contexts. In dog liver tissue, both CBD and CBDA inhibited the breakdown of tramadol, a common pain medication. CBDA inhibited an additional metabolic pathway that CBD did not, meaning CBDA’s interaction profile may be slightly broader than CBD’s for certain drugs.9PubMed. Cannabidiol and cannabidiolic acid: Preliminary in vitro evaluation of metabolism and drug-drug interactions involving canine cytochrome P-450, UDP-glucuronosyltransferase, and P-glycoprotein Whether the same extra pathway matters in humans has not been tested yet, but the finding is a signal worth noting.
The practical takeaway: if you take warfarin, certain anti-seizure drugs, some diabetes medications, or other drugs metabolized primarily through CYP2C9, adding a CBDA product without telling your doctor is risky. The interaction could change how much of your medication is active in your body at any given time.
Liver Enzyme Elevation
Elevated liver enzymes are a known side effect of high-dose CBD, and since CBDA converts to CBD in the body and shares many of the same metabolic pathways, the concern extends to CBDA as well. A 36-week study in dogs receiving CBD oil at two dose levels found that the liver enzyme alkaline phosphatase (ALP) rose significantly in dogs given CBD, compared to those given a placebo. One dog at the higher dose showed ALP levels seven to ten times above the normal upper limit, though the values came back down within two weeks after the study ended.10Journal of Veterinary Internal Medicine. Tolerability of long-term cannabidiol supplementation to healthy adult dogs
This study used CBD oil rather than CBDA specifically, and dogs metabolize cannabinoids differently than humans. But the finding lines up with what is seen in human epilepsy patients on high-dose pharmaceutical CBD, where liver enzyme monitoring is standard practice. Given that CBDA achieves higher blood levels per milligram than CBD, the possibility that it could stress the liver at lower milligram doses is at least plausible. Anyone using CBDA products regularly, especially at higher doses, would be wise to ask for periodic liver enzyme checks.
CBDA as a COX-2 Inhibitor
One of CBDA’s most distinctive pharmacological properties is that it selectively inhibits cyclooxygenase-2, or COX-2, the same enzyme targeted by anti-inflammatory drugs like celecoxib. CBDA inhibited COX-2 with about nine times more selectivity than it showed for COX-1.11PubMed Central. Cannabidiolic acid as a selective cyclooxygenase-2 inhibitory component in cannabis This selectivity is actually a desirable feature for reducing inflammation and pain, because COX-1 inhibition is what drives many of the stomach-related side effects of traditional anti-inflammatory drugs like ibuprofen.
But COX-2 inhibition carries its own set of concerns. The class of pharmaceutical COX-2 inhibitors (sometimes called “coxibs”) became infamous when rofecoxib (Vioxx) was pulled from the market due to elevated cardiovascular risk with long-term use. It is a stretch to assume CBDA at supplement doses would carry the same risk, since the concentrations reached in typical use are far below what pharmaceutical COX-2 inhibitors achieve. Still, the mechanism is shared, and for people already at elevated cardiovascular risk or taking other anti-inflammatory drugs, the overlap is worth being aware of. No human study has measured whether CBDA at any dose affects cardiovascular outcomes, so this remains a theoretical concern rather than a documented side effect.
Sedation and Mood Effects
Drowsiness is one of the most commonly reported side effects of CBD, and since CBDA acts on some of the same brain receptors, mild sedation is expected with CBDA too. The 5-HT1A serotonin receptor, which CBDA activates at remarkably low doses, is involved in anxiety regulation, mood, and sleep. A stabilized derivative of CBDA (called HU-580) reduced depression-like behavior in two animal models of depression, working through the same serotonin pathway.12PubMed. Acute oral cannabidiolic acid methyl ester reduces depression-like behavior in two genetic animal models of depression That is encouraging from a therapeutic standpoint, but it also means CBDA may produce mood-altering effects that some people experience as tiredness, emotional blunting, or feeling “off.”
There is no evidence that CBDA produces a high or psychoactive effect in the way THC does. It does not bind meaningfully to the CB1 receptors that mediate THC’s intoxication. But working through serotonin receptors means it is not neurologically inert. If you are taking an SSRI, an SNRI, or another serotonergic medication, adding a compound that also activates 5-HT1A receptors introduces at least a theoretical risk of excessive serotonin signaling. No case reports of this interaction exist for CBDA specifically, but the pharmacology warrants caution, especially since CBDA’s higher bioavailability means more of it reaches the brain.
Allergic Reactions
Cannabis-related allergies are a real and underappreciated phenomenon. Cannabis plants contain formally recognized allergens that can trigger both immediate allergic reactions (the kind that cause hives, itching, and in rare cases anaphylaxis) and delayed reactions (contact dermatitis, rashes).13PubMed Central. Cannabis-related allergies: An international overview and consensus recommendations The post-marketing safety review of a full-spectrum hemp extract found that skin rashes were the most commonly reported side effect for topically applied products.14PubMed. Post Marketing Safety of Plus CBDâ„¢ Products, a Full Spectrum Hemp Extract: A 2-Year Experience
These allergic responses are not specific to CBDA as a molecule. They are driven by proteins in the plant material, and any hemp or cannabis product that retains plant proteins could provoke them. But CBDA-rich products tend to be less processed than purified CBD isolates, precisely because heating and extensive purification would convert the CBDA to CBD. That means CBDA oils, raw juices, and minimally processed tinctures may retain more of the plant’s allergenic proteins. If you have a known sensitivity to cannabis, hemp, or related plants like hops, this is worth factoring in.
Dose Unpredictability and Biphasic Responses
One underappreciated complication with CBDA is that its effects may not scale linearly with dose. Clinical case reports in epilepsy have documented biphasic dose-response patterns with cannabinoid preparations, where a moderate dose produces a therapeutic effect but a higher dose can reduce or reverse that benefit.15PubMed. The current status of artisanal cannabis for the treatment of epilepsy in the United States Some of the animal anti-nausea data hints at a similar pattern, with CBDA effective at microgram-level doses and its activity mediated by a receptor system known for biphasic behavior.
For side effects, the implication is not just “more CBDA means more side effects.” It is that the nature of the effects may shift at different dose ranges. A low dose might calm the stomach; a higher dose might upset it. A low dose might ease anxiety; a higher one might increase drowsiness beyond what is useful. Without dose-finding studies in humans, you are essentially experimenting on yourself, and the product labels on the market offer little guidance because the regulatory framework does not require it.
CBDA in Breastmilk
For nursing parents, there is a specific concern. Researchers developing methods to detect cannabinoids in breastmilk included CBDA in their assay and detected it in real postpartum samples from mothers who had used cannabis or CBD products.16Oxford Academic / Journal of Analytical Toxicology. Analysis of cannabinoids and semi-synthetic cannabinoids in authentic breastmilk samples by liquid chromatography-tandem mass spectrometry The study was designed to validate the detection method rather than to measure health effects on infants, so we do not know what, if anything, CBDA in breastmilk does to a developing baby. But the fact that it shows up there at detectable concentrations means it crosses into milk, and infants have immature liver enzyme systems that may struggle to metabolize cannabinoids efficiently. Major health organizations already advise against cannabis use during breastfeeding, and that advice logically extends to CBDA-containing products until evidence suggests otherwise.
What a Pilot Study in Humans Actually Found
One of the few human studies that tracked CBDA after oral dosing was a pilot study in patients with medication-overuse headache. Participants received oral cannabis preparations, and researchers monitored blood pressure, heart rate, and adverse symptoms. CBDA turned out to be one of the most widely absorbed cannabinoids among those measured. No serious adverse events were reported during the study.17European Journal of Clinical Pharmacology. Pharmacokinetics and tolerability of oral cannabis preparations in patients with medication overuse headache (MOH)-a pilot study That is reassuring as far as it goes, but pilot studies are small by design, short in duration, and intended to check feasibility rather than safety. A lack of serious events in a handful of participants over a short period does not rule out side effects that would emerge in thousands of people or after months of use.
The broader message from that pilot aligns with what the animal and lab data suggest: CBDA at ordinary doses does not appear acutely dangerous. The risks that concern pharmacologists are subtler and longer-term. They are about drug interactions sneaking up on people who combine CBDA with prescription medications, about liver stress that accumulates gradually, and about a supplement market where products vary wildly in actual CBDA content because the molecule keeps converting to CBD on the shelf. If you are considering CBDA, the most practical precaution is to treat it the way you would any other pharmacologically active supplement: start low, tell your prescribers, and pay attention to what your body reports back.